Palvella Therapeutics (PVLA) Total Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Liabilities data on file, last reported at $31.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $31.4 million, up 31.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.4 million (up 31.78% YoY), and the FY2025 annual result was $31.6 million, up 23.21% from the prior year.
• Total Liabilities steadied at $31.4 million in Q1 2026 per PVLA's latest filing, from $31.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $107.9 million in Q3 2024 and troughed at $11.4 million in Q4 2023.
• A 5-year average of $54.4 million and a median of $47.0 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities sank 83.08% in 2023, then jumped 273.89% in 2024.
• A 5-year view of Total Liabilities shows it stood at $67.6 million in 2022, then slumped by 83.08% to $11.4 million in 2023, then surged by 124.25% to $25.6 million in 2024, then climbed by 23.21% to $31.6 million in 2025, then slipped by 0.41% to $31.4 million in 2026.
• Business Quant data shows PVLA's Total Liabilities at $31.4 million in Q1 2026, $31.6 million in Q4 2025, and $28.3 million in Q3 2025.